Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Dalfampridine | hsa00061 | Fatty acid biosynthesis | 4.83E-02 | 1 | P33121 | ACSL1 | More | | Dalfampridine | hsa00190 | Oxidative phosphorylation | 3.50E-02 | 2 | Q16718, Q13488 | NDUFA5, TCIRG1 | More | | Dalfampridine | hsa00600 | Sphingolipid metabolism | 3.01E-02 | 2 | Q9BX95, P06280 | SGPP1, GLA | More | | Dalfampridine | hsa00620 | Pyruvate metabolism | 4.20E-02 | 2 | P40926, P14550 | MDH2, AKR1A1 | More | | Dalfampridine | hsa01100 | Metabolic pathways | 4.56E-02 | 11 | P15144, P32320, P06280, P24666, P33121, P42330, Q13093, Q9NY28, Q9BX95, P09960, Q16718 | ANPEP, CDA, GLA, ACP1, ACSL1, AKR1C3, PLA2G7, GALNT8, SGPP1, LTA4H, NDUFA5 | More | | Dalfampridine | hsa03010 | Ribosome | 3.56E-06 | 14 | P62753, P42677, P32969, P40429, P62917, P46776, Q9H0U6, Q07020, P62910, Q02878, P36578, P05386, P62249, P23396 | RPS6, RPS27, RPL9, RPL13A, RPL8, RPL27A, MRPL18, RPL18, RPL32, RPL6, RPL4, RPLP1, RPS16, RPS3 | More | | Dalfampridine | hsa03020 | RNA polymerase | 9.86E-07 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Dalfampridine | hsa04024 | cAMP signaling pathway | 1.53E-02 | 4 | P49019, P22694, P20020, P48058 | HCAR3, PRKACB, ATP2B1, GRIA4 | More | | Dalfampridine | hsa04145 | Phagosome | 2.75E-02 | 4 | Q15080, P14598, P68371, Q13488 | NCF4, NCF1, TUBB2C, TCIRG1 | More | | Dalfampridine | hsa04217 | Necroptosis | 1.70E-02 | 5 | P01568, Q13489, P08238, O43633, Q08752 | IFNA21, BIRC3, HSP90AB1, CHMP2A, PPID | More | | Dalfampridine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.11E-02 | 4 | P17252, O60880, P26717, P26715 | PRKCA, SH2D1A, KLRC2, KLRC1 | More | | Dalfampridine | hsa04713 | Circadian entrainment | 1.69E-02 | 3 | P17252, P48058, P22694 | PRKCA, GRIA4, PRKACB | More | | Dalfampridine | hsa04714 | Thermogenesis | 3.16E-02 | 3 | P22694, P33121, Q16718 | PRKACB, ACSL1, NDUFA5 | More | | Dalfampridine | hsa04721 | Synaptic vesicle cycle | 1.14E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Dalfampridine | hsa04723 | Retrograde endocannabinoid signaling | 1.20E-03 | 4 | P17252, P48058, P22694, Q16718 | PRKCA, GRIA4, PRKACB, NDUFA5 | More | | Dalfampridine | hsa04724 | Glutamatergic synapse | 1.31E-02 | 3 | P48058, P22694, P17252 | GRIA4, PRKACB, PRKCA | More | | Dalfampridine | hsa04726 | Serotonergic synapse | 2.62E-02 | 3 | P22694, P17252, P31645 | PRKACB, PRKCA, SLC6A4 | More | | Dalfampridine | hsa04911 | Insulin secretion | 3.01E-02 | 2 | P22694, P17252 | PRKACB, PRKCA | More | | Dalfampridine | hsa04913 | Ovarian steroidogenesis | 1.28E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Dalfampridine | hsa04918 | Thyroid hormone synthesis | 3.01E-02 | 2 | P22694, P17252 | PRKACB, PRKCA | More | | Dalfampridine | hsa04925 | Aldosterone synthesis and secretion | 9.86E-03 | 3 | P17252, P22694, P20020 | PRKCA, PRKACB, ATP2B1 | More | | Dalfampridine | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 9.85E-05 | 3 | P20020, P17252, P22694 | ATP2B1, PRKCA, PRKACB | More | | Dalfampridine | hsa04962 | Vasopressin-regulated water reabsorption | 6.61E-03 | 2 | P22694, Q13561 | PRKACB, DCTN2 | More | | Dalfampridine | hsa04970 | Salivary secretion | 7.14E-03 | 3 | P22694, P20020, P17252 | PRKACB, ATP2B1, PRKCA | More | | Dalfampridine | hsa04972 | Pancreatic secretion | 1.48E-03 | 2 | P20020, P17252 | ATP2B1, PRKCA | More | | Dalfampridine | hsa04976 | Bile secretion | 3.01E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Dalfampridine | hsa05010 | Alzheimer disease | 7.11E-03 | 9 | O15239, P13073, P18848, O15169, P67870, P05141, P12236, P28070, P43686 | NDUFA1, COX4I1, ATF4, AXIN1, CSNK2B, SLC25A5, SLC25A6, PSMB4, PSMC4 | More | | Dalfampridine | hsa05012 | Parkinson disease | 2.14E-02 | 7 | O15239, P13073, P05141, P12236, P18848, P28070, P43686 | NDUFA1, COX4I1, SLC25A5, SLC25A6, ATF4, PSMB4, PSMC4 | More | | Dalfampridine | hsa05016 | Huntington disease | 2.46E-05 | 3 | Q9GZM3, P52435, Q9NYC9 | POLR2J2, POLR2J, DNAH9 | More | | Dalfampridine | hsa05017 | Spinocerebellar ataxia | 4.66E-02 | 4 | P28070, P43686, P05141, P12236 | PSMB4, PSMC4, SLC25A5, SLC25A6 | More | | Dalfampridine | hsa05020 | Prion disease | 1.55E-03 | 10 | P46531, O15239, P13073, P18848, P05141, P12236, P28070, P43686, P67870, P51636 | NOTCH1, NDUFA1, COX4I1, ATF4, SLC25A5, SLC25A6, PSMB4, PSMC4, CSNK2B, CAV2 | More | | Dalfampridine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 5.20E-04 | 15 | P67870, O15239, Q16718, P13073, P18848, Q13561, P48058, P05141, P12236, P17252, P20333, O15169, Q08752, P28070, P43686 | CSNK2B, NDUFA1, NDUFA5, COX4I1, ATF4, DCTN2, GRIA4, SLC25A5, SLC25A6, PRKCA, TNFRSF1B, AXIN1, PPID, PSMB4, PSMC4 | More | | Dalfampridine | hsa05031 | Amphetamine addiction | 1.69E-02 | 3 | P48058, P22694, P17252 | GRIA4, PRKACB, PRKCA | More | | Dalfampridine | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | Dalfampridine | hsa05110 | Vibrio cholerae infection | 3.01E-02 | 2 | P17252, P22694 | PRKCA, PRKACB | More | | Dalfampridine | hsa05171 | Coronavirus disease - COVID-19 | 1.08E-04 | 13 | P23396, P62753, P62249, P42677, P40429, P36578, Q02878, P62917, P32969, Q07020, P46776, P62910, P05386 | RPS3, RPS6, RPS16, RPS27, RPL13A, RPL4, RPL6, RPL8, RPL9, RPL18, RPL27A, RPL32, RPLP1 | More | | Dalfampridine | hsa05224 | Breast cancer | 3.88E-02 | 3 | P46531, Q9UM47, O15169 | NOTCH1, NOTCH3, AXIN1 | More | | Dalfampridine | hsa05415 | Diabetic cardiomyopathy | 2.75E-02 | 4 | P17252, P14598, Q15080, Q16718 | PRKCA, NCF1, NCF4, NDUFA5 | More | | |